Celldex Therapeutics, Inc. — Director's Dealing 2016

Sep 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-09-02

Reporting Person: CATLIN AVERY W (Sr. VP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-09-02	Common Stock, par value $0.001 per share	M	10000	$2.80	Acquired	83586	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-09-02	Employee Stock Option (right to buy)	$2.80	M	10000	Disposed	2021-08-05	Common Stock (10000)	Direct

Footnotes

F1: As of August 5, 2015, the option is fully vested.